SCHEMBL637818

SCHEMBL637818

Cc1c(-c2ccc(OCc3ccccc3)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(OCc3ccccc3)cc12

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 20/20 0.79
ESR2 Q92731 2/20 0.75
MLNR O43193 1/20 0.75
ABCB11 O95342 1/20 0.75
NR3C1 P04150 1/20 0.75
CHRM2 P08172 1/20 0.75
HTR1A P08908 1/20 0.75
ADRA2A P08913 1/20 0.75
ADORA3 P0DMS8 1/20 0.75
CHRM1 P11229 1/20 0.75
DRD2 P14416 1/20 0.75
ADRA2B P18089 1/20 0.75
ADRA2C P18825 1/20 0.75
DRD1 P21728 1/20 0.75
SLC6A2 P23975 1/20 0.75
HTR2A P28223 1/20 0.75
SLC6A4 P31645 1/20 0.75
ADRA1A P35348 1/20 0.75
PTGS2 P35354 1/20 0.75
OPRM1 P35372 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103459 1.00 ESR1 (0.79) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL4165462 1.00 ESR1 (0.79) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL22692809 0.99 ESR1 (0.77) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL3419820 0.98 ESR1 (0.82) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL3413818 0.97 ESR1 (0.78) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL5973173 0.97 ESR1 (0.82) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL3414356 0.97 ESR1 (0.78) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL1546005 0.97 ESR1 (0.82) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL3412644 0.97 ESR1 (0.78) ESR1ESR2MLNRABCB11NR3C1
SCHEMBL3416547 0.96 ESR1 (0.79) ESR1ESR2MLNRABCB11NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844047-B2 Process for the preparation of bazedoxifene ERREGIERRE S.P.A. (IT) 2020-11-24 US claimed
CN-110627704-A Preparation method of bazedoxifene 艾瑞吉瑞股份公司 2019-12-31 CN claimed
EP-2252585-B1 METHODS OF PREPARING POLYMORPHIC FORM A OF BAZEDOXIFENE ACETATE WYETH LLC (US) 2013-11-06 EP claimed
US-8569483-B2 Process for the preparation of bazedoxifene acetate and intermediates thereof Divi's Laboratories, Ltd. (IN) 2013-10-29 US claimed
US-20120330008-A1 NOVEL PROCESS FOR THE PREPARATION OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF DIVI'S LABORATORIES LIMITED (IN) 2012-12-27 US claimed
EP-2419406-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF Sandoz AG (CH) 2012-02-22 EP claimed
WO-2010118997-A1 PROCESSES FOR THE SYNTHESIS OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF SANDOZ AG (CH) 2010-10-21 WO claimed
EP-2185510-A2 NEW SALTS OF BAZEDOXIFENE Zentiva, K.S. (CZ) 2010-05-19 EP claimed
WO-2009012734-A2 NEW SALTS OF BAZEDOXIFENE ZENTIVA A.S. (CZ) 2009-01-29 WO claimed
EP-1051179-B1 ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES WYETH CORP (US) 2005-09-14 EP claimed
US-6326392-B1 ADMINISTERING MIXTURE AMERICAN HOME PRODUCTS CORPORATION 2001-12-04 US claimed
US-6326367-B1 THERAPY FOR OVARIAN CANCER AMERICAN HOME PRODUCTS CORPORATION 2001-12-04 US claimed
EP-0802183-B1 Estrogenic agents AMERICAN HOME PROD (US) 2001-10-10 EP claimed
US-20010021719-A1 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents WYETH 2001-09-13 US claimed
US-6232307-B1 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS USEFUL AS ESTROGENIC AGENTS AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 US claimed
US-6225308-B1 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS WHICH ARE USEFUL AS ESTROGENIC AGENTS AMERICAN HOME PRODUCTS CORPORATION 2001-05-01 US claimed
EP-1051179-A2 ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-15 EP claimed
US-5998402-A OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY AMERICAN HOME PRODUCTS CORPORATION (US) 1999-12-07 US claimed
WO-1999024027-A2 ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1999-05-20 WO claimed
EP-0802183-A1 Estrogenic agents AMERICAN HOME PRODUCTS CORPORATION (US) 1997-10-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021719-A1 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents ESR1, ESR2, GPER1 ESR1 1/4885ESR2 2/4885MLNR 874/4885
US-20120330008-A1 NOVEL PROCESS FOR THE PREPARATION OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF CYP19A1, HSD17B11, SULT1E1 ESR1 37/4885ESR2 16/4885MLNR 1768/4885
US-10844047-B2 Process for the preparation of bazedoxifene CYP19A1, CYP3A5, CYP4A11 ESR1 29/4885ESR2 74/4885MLNR 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.